Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
|Lymphoma, B-Cell||Drug: cyclophosphamide Drug: etoposide Drug: rituximab Drug: cytarabine Drug: doxorubicin Drug: tositumomab||Phase 2|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Dose-Intensive Chemotherapy Combined With Monoclonal Antibody Therapy and Targeted Radioimmunotherapy for Untreated Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma|
- 1 Year Progression-free Survival Rate [ Time Frame: 1 year ]Progression-free survival is measured from the first day of induction chemotherapy to the date of progression, relapse or death. Definitions of response criteria are as described by Cheson. Progressive Disease: >50% increase from nadir in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal node for PDs or nonresponders, appearance of any new lesion during or at the end of therapy.
- Disease-free Survival [ Time Frame: 10 years ]Disease-free survival is measured from the date of CR or CRu to date of relapse or death
- Overall Survival [ Time Frame: 10 years ]Overall Survival is measured from the first day of chemotherapy until death from any cause.
- Overall Response [ Time Frame: up to 1 year ]
Percent of subjects who achieved a complete response (CR) or partial response (PR) any time during the treatment period.
CR = complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.
- >/= 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
- No increase should be observed in the size of other nodes, liver, or spleen.
- Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter.
- Except splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
- Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders.
- No new sites of disease should be observed.
- Secondary Malignancies [ Time Frame: 10 years ]The number of patients who develop secondary malignancies including solid tumors, acute leukemia and myelodysplasia or other bone marrow failure syndromes.
|Actual Study Start Date:||June 18, 2005|
|Study Completion Date:||November 3, 2016|
|Primary Completion Date:||April 8, 2012 (Final data collection date for primary outcome measure)|
Experimental: Induction + Consolidation + Bexxar
Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
Other Name: Cytoxan®Drug: etoposide
300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
Other Name: VP-16Drug: rituximab
375mg/m2 each week x 4 weeks of induction, beginning on day 1
Other Name: RituxanDrug: cytarabine
3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
Other Name: Ara-CDrug: doxorubicin
45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
Other Name: AdriamycinDrug: tositumomab
450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
Other Name: Bexxar
Please refer to this study by its ClinicalTrials.gov identifier: NCT00577629
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||David Rizzieri, MD||Duke Unversity Medical Center|